Agilent Technologies Inc
F:AG8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (5.6), the stock would be worth €119.71 (22% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.6 | €98.14 |
0%
|
| 3-Year Average | 5.6 | €119.71 |
+22%
|
| 5-Year Average | 5.8 | €124.46 |
+27%
|
| Industry Average | 5.1 | €107.92 |
+10%
|
| Country Average | 2.4 | €52 |
-47%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
€32.5B
|
/ |
Feb 2026
$7.1B
|
= |
|
|
€32.5B
|
/ |
Oct 2026
$7.5B
|
= |
|
|
€32.5B
|
/ |
Oct 2027
$8B
|
= |
|
|
€32.5B
|
/ |
Oct 2028
$8.5B
|
= |
|
|
€32.5B
|
/ |
Oct 2029
$9.4B
|
= |
|
|
€32.5B
|
/ |
Oct 2030
$10.4B
|
= |
|
|
€32.5B
|
/ |
Oct 2031
$9.5B
|
= |
|
|
€32.5B
|
/ |
Oct 2032
$10.1B
|
= |
|
|
€32.5B
|
/ |
Oct 2033
$10.6B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Agilent Technologies Inc
F:AG8
|
32.5B EUR | 4.6 | 25.2 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 327.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 3.9 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 5.1 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
329.9B CNY | 7.3 | 17.3 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.1B CHF | 5 | -119.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 9.3 | 45.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 1.7 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 6.4 | 29.6 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
20.7B USD | 6.4 | 38.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Agilent Technologies Inc
Glance View
Agilent Technologies Inc., a spin-off from Hewlett-Packard in 1999, has cultivated a niche in the vibrant landscape of the life sciences, diagnostics, and applied chemical markets. This California-based company, born from the legacy of one of Silicon Valley’s pioneers, has carved out its identity by providing sophisticated analytical instrumentation, software, services, and consumables for a wide range of applications. Agilent's businesses are stitched together by an underlying technology expertise, which forms the bedrock for its product lines that serve an increasing demand for precise and reliable analytical measurements. From cutting-edge liquid chromatography to mass spectrometry and genetic analysis systems, Agilent's offerings are geared towards supporting research and quality control processes across various industries, including pharmaceuticals, food safety, and environmental testing. The company's commitment to innovation and quality has consistently positioned it as a trusted partner in advancing the capabilities of laboratories worldwide. Agilent's revenue generation hinges on a strategic blend of product sales and services. The core of its business model revolves around not just selling instruments, but also establishing long-term relationships through service agreements, maintenance, and training. This recurring service revenue complements the sale of consumables and parts required for the operation of their sophisticated instruments. Additionally, Agilent has strategically expanded its footprint in the diagnostics market, providing instruments and reagents used in pathology laboratories, further diversifying its income streams. With a deliberate focus on high-growth areas, including genomics and cancer diagnostics, Agilent continues to leverage its technological prowess and industry expertise to capture market share in sectors that are inherently driven by the necessity for innovation and regulatory compliance. Through an intricate balance of hardware sales and consistent after-sale support, Agilent steadily maintains its role as a formidable player in the analytical instrumentation sector.